MARKET

EYPT

EYPT

EyePoint
NASDAQ
3.620
-0.030
-0.82%
After Hours: 3.618 -0.002 -0.07% 19:59 09/25 EDT
OPEN
3.650
PREV CLOSE
3.650
HIGH
3.705
LOW
3.555
VOLUME
2.25M
TURNOVER
--
52 WEEK HIGH
19.11
52 WEEK LOW
3.415
MARKET CAP
312.09M
P/E (TTM)
-0.9673
1D
5D
1M
3M
1Y
5Y
1D
These beaten-down stocks could bounce back in January, if history is any guide
MarketWatch · 5d ago
Weekly Report: what happened at EYPT last week (0914-0918)?
Weekly Report · 5d ago
Xenon Pharmaceuticals, Steel Dynamics, Nucor And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
Benzinga · 09/18 12:01
Weekly Report: what happened at EYPT last week (0907-0911)?
Weekly Report · 09/14 09:12
EyePoint updates DURAVYU Phase 3 wet AMD data
TipRanks · 09/10 11:31
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), EyePoint Pharmaceuticals (EYPT) and Abbott Laboratories (ABT)
TipRanks · 09/10 10:30
Weekly Report: what happened at EYPT last week (0831-0904)?
Weekly Report · 09/07 09:11
Aclaris, EyePoint, Vertex, GitLab, NioCorp Trending With Analysts
TipRanks · 09/05 09:01
More
About EYPT
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.

Webull offers EyePoint Inc stock information, including NASDAQ: EYPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EYPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EYPT stock methods without spending real money on the virtual paper trading platform.